Don’t let the high cost of brand specialty atopic dermatitis biologics stand between you and the treatment you need. We help eligible patients access Ebglyss (lebrikizumab) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
The Ebglyss Prescription Assistance Program is a manufacturer-sponsored initiative that provides Ebglyss at little or no medication cost to qualifying patients based on income and insurance status. The program is designed for atopic dermatitis patients who are uninsured or underinsured, as well as Medicare Part D beneficiaries.
Navigating the program on your own means dealing with eligibility verification, dermatology coordination, prior-authorization documentation, specialty pharmacy logistics, and renewal deadlines.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your enrollment, from initial application through ongoing refill coordination and annual re-certification — so you focus on your skin health, not paperwork.
| Pharmacy(With Coupon) | PrIce (30-Day)* | You Save W/ Us |
|---|---|---|
| Walgreens | ~$4,400.00 | Save ~$4,330/mo |
| CVS Pharmacy | ~$4,500.00 | Save ~$4,430/mo |
| Walmart | ~$3,900.00 | Save ~$3,830/mo |
| Costco | ~$3,700.00 | Save ~$3,630/mo |
| Specialty Pharmacy | ~$3,800.00 | Save ~$3,730/mo |
*Retail prices are estimates based on public data and vary by pharmacy. Coupon prices from GoodRx and SingleCare as of April 2026. Afford My Prescriptions Advocacy Service bypasses retail pricing by using drug manufacturer programs to secure your medication for you—independent of dosage or retail price.
1 Medications
2 Medications
3 Medications
4+ Medications
The Patient Assistance Program is free to apply for and provides Ebglyss at no medication cost if approved. But the process involves detailed applications, dermatology coordination, prior-authorization documentation, specialty pharmacy logistics, and ongoing renewal management. Our $69.95/month service covers full advocacy: applications, doctor coordination, documentation, refill management, and annual re-enrollment.
Complete a simple eligibility form so our team can determine if you may qualify for medication assistance programs.
Our specialists help gather documentation, complete applications, and coordinate with program providers.
Once approved, you may receive your medication through the assistance program while we help manage ongoing paperwork and renewals.
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Ebglyss:
Prices fluctuate — savings aren’t guaranteed month-to-month
Copay accumulators may prevent savings from counting toward your deductible
Coupon cards expire and require constant renewal
Still $3,500–$4,500 per month even with the best discount
Cannot be used with Medicare, Medicaid, or government insurance
Fixed $69.95/month — never changes regardless of retail price
Medication supplied directly through the assistance program
We manage all paperwork, refills, and annual renewals
Medicare Part D patients accepted
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Ebglyss assistance.
Ebglyss (lebrikizumab) is a once-monthly maintenance injectable biologic for moderate-to-severe atopic dermatitis (eczema). It is approved for adults and adolescents 12 and older weighing at least 40 kg whose disease is not adequately controlled with topical prescription therapies. Ebglyss is given by subcutaneous injection — typically a loading phase of higher-frequency dosing followed by once-monthly maintenance dosing.
How It Works:
Atopic dermatitis is driven by an overactive type-2 immune response where the cytokine IL-13 causes skin-barrier dysfunction, itch, and rashes. Ebglyss is a monoclonal antibody that selectively binds to IL-13, preventing it from interacting with its receptor. By neutralizing this specific cytokine, the medication reduces inflammation to improve skin clearance and quality of life. Because it targets only IL-13 rather than multiple proteins, it is generally well-tolerated.
Form and Use:
Ebglyss is administered through subcutaneous injections, which can be self-administered at home after proper training. The treatment begins with a 500 mg dose at Week 0 and Week 2, followed by 250 mg every two weeks until Week 16. After this initial period, the schedule shifts to a monthly maintenance dose of 250 mg every four weeks.
Generic Availability:
As of 2026, there are no generic or biosimilar versions of Ebglyss available in the U.S. While other FDA-approved biologics like Dupixent, Adbry, and Nemluvio exist, the choice between them depends on a patient’s treatment history and dosing preferences. Additionally, oral and topical JAK inhibitors serve as alternative options for managing atopic dermatitis.
Warnings:
Patients should be aware of potential hypersensitivity reactions and the risk of helminth infections while using this medication. Conjunctivitis is a common side effect of this drug class, and any persistent eye redness or discomfort should be reported to a dermatology team. Furthermore, it is advised that patients avoid receiving live vaccines during their treatment with Ebglyss.
The average retail price runs approximately $3,500–$4,500 per month. Annual costs commonly reach $40,000–$55,000 for ongoing therapy. Through AffordMyPrescriptions, qualifying patients receive Ebglyss at no medication cost — our $69.95 monthly fee covers full advocacy and program management.
Ebglyss is given by subcutaneous injection. The recommended schedule is 500 mg at Week 0 and Week 2 (loading phase), then 250 mg every two weeks through Week 16, then 250 mg every four weeks (monthly maintenance) thereafter. The injection can be self-administered at home after training.
Yes. Other approved biologics include dupilumab (Dupixent), tralokinumab (Adbry), and nemolizumab (Nemluvio). Oral and topical JAK inhibitors are also available. Whether any of these is a better clinical fit depends on prior treatments, dosing preferences, side-effect profile, and tolerability. We mention this directly because if a different therapy on a more accessible assistance pathway would work, that may be a better path.
Yes. Medicare Part D beneficiaries can typically qualify for Betaseron Patient Assistance, especially if you have not yet reached catastrophic coverage or are facing specialty-tier copays you cannot afford. Note that the manufacturer’s commercial copay card is a separate program reserved for commercially insured patients only — but the underlying PAP supports Medicare patients who meet income criteria.
After the initial 16-week induction phase, Ebglyss can be given every four weeks for ongoing maintenance therapy. This is one of the longest dosing intervals among atopic dermatitis biologics, which makes ongoing therapy more convenient for many patients.
If your initial application is denied, we explore alternative savings paths on your behalf — including independent foundations such as the PAN Foundation, HealthWell Foundation, or the National Eczema Association, the manufacturer’s copay savings program if you have commercial insurance, or asking your dermatology team whether a different atopic dermatitis biologic or JAK inhibitor would be appropriate. If we cannot find a path, you will not be charged our service fee.
If you are struggling with the high cost of Ebglyss, our team may be able to help you access assistance programs designed to make brand specialty atopic dermatitis biologics affordable. Check your eligibility today.
Start free by filling out a simple online form.
Our specialist will contact you for a quick welcome call.
Our team handles everything, so you can focus on your health.